Participant flow

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma · Source last updated 2025-09-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma Bortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1

   id

   FG000

   title

   Tandem Transplantation With Melphalan and Bortezomib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Screen Failure

   3. reasons

      1. group Id

         FG000

         num Subjects

         39

      type

      Did not move forward with 2nd Transplant

   4. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         148

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         92

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         56

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice